Biotech · Private company
Affimed GmbH
Track this companyFree. Adds Affimed GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- 14 mg AFM24Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- 160 mg AFM24Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- 320 mg AFM24Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- 40 mg AFM24Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- 480 mg AFM24Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- 80 mg AFM24Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- AB-101Phase 2 · Relapsed or Refractory Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AFM13Phase 2 · Peripheral T Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AFM13Phase 2 · Relapsed or Refractory Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AFM24Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Atezolizumab 840 MG in 14 ML InjectionPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Relapsed or Refractory Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 2 · Relapsed or Refractory Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Interleukin-2Phase 2 · Relapsed or Refractory Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AFM11Phase 1 · Relapsed B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AFM13Phase 1 · Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLPHASE2 · TERMINATED · started Oct 10, 2023ClinicalTrials.gov NCT05883449 · fetched Nov 12, 2026
- Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing CancersPHASE1_PHASE2 · TERMINATED · started Nov 19, 2021ClinicalTrials.gov NCT05109442 · fetched Nov 12, 2026
- Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersPHASE1_PHASE2 · TERMINATED · started Nov 3, 2021ClinicalTrials.gov NCT05099549 · fetched Nov 12, 2026
- Study to Assess AFM24 in Advanced Solid CancersPHASE1_PHASE2 · TERMINATED · started Apr 7, 2020ClinicalTrials.gov NCT04259450 · fetched Nov 12, 2026
- Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis FungoidesPHASE2 · COMPLETED · started Nov 13, 2019ClinicalTrials.gov NCT04101331 · fetched Nov 12, 2026
- Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaPHASE1 · COMPLETED · started May 1, 2016ClinicalTrials.gov NCT02665650 · fetched Nov 12, 2026
- Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHLPHASE1 · TERMINATED · started Apr 1, 2014ClinicalTrials.gov NCT02106091 · fetched Nov 12, 2026